Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry
Hunter C. Gits(Pediatric Oncology Group), Carl Koschmann(University of Michigan)
Cited by 12
Related Papers
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
|Journal of Clinical Investigation|2024|44
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis
|Cancer Cell|2025|21
Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM
|Cancer Discovery|2025|4
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1